Replimune Group, Inc. (REPL)
5.21
+0.05
(+0.97%)
USD |
NASDAQ |
May 21, 16:00
5.33
+0.12
(+2.30%)
After-Hours: 19:59
Replimune Group Research and Development Expense (TTM) : 222.70M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| REGENXBIO, Inc. | 217.03M |
| Catalyst Pharmaceuticals, Inc. | 11.48M |
| Spyre Therapeutics, Inc. | 190.44M |
| Bristol Myers Squibb Co. | 9.494B |
| ANI Pharmaceuticals, Inc. | 51.70M |